Veritable’s Lexicon Pharmaceuticals LXRX Stock Holding History

Veritable’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-2,857	Closed	-$43K	–	959
2013 Q2	$43K	Buy	+2,857	New	+$43.4K	﹤0.01%	933

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Veritable's LXRX Position: Q3 2013 in Review

Veritable sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2013, closing a stake of 2,857 shares — an estimated $43K sold.

Veritable first reported a position in LXRX in Q2 2013 and held it in 1 quarter. The position peaked at $43K in Q2 2013. 102 funds tracked by Wall St. Rank hold LXRX as of Q3 2013.

Veritable reported no remaining Lexicon Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
Veritable sold 2,857 Lexicon Pharmaceuticals shares in Q3 2013, an estimated $43K.
Veritable first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 1 quarter.
Veritable's Lexicon Pharmaceuticals position peaked at $43K in Q2 2013.
102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2013.

Based on Veritable's 13F filing for Q3 2013, filed 13 Nov 2013.